Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q3 FY2020 Earnings Presentation
18 slides from Advanced Enzyme Technologies's earnings presentation, Feb 6, 2020
Slide 1: Advanced Enzyme Technologies Limited – Where ENZYME is Life
Advanced Enzyme Technologies Limited Where ENZYME is Life Earnings Presentation | Q3FY20
Slide 2: Disclaimer
2 Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views
Slide 3: Company Overview: What are enzymes?
3 Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve effic
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
4 Advanced Enzyme Technologies Limited – A Rising Global Star Revenue (₹ mn) 1st Indian enzyme company Highest market share in India Listed integrated enzyme player globally 4,196 2nd 2nd Amongst Top 15 Global Enzyme Companies 2,321 Manufacturing Units – 7 R&D Units – 7 FY 15 FY 19 India - 5 USA - 2
Slide 5: Results Summary – Q3FY20 (Consolidated)
5 Results Summary – Q3FY20 (Consolidated) *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,119 529 1,017 417 346 253 Q3FY19 Q3FY20 Q3FY19 Q3FY20 Q3FY19 Q3FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Bio-Processing -24% -1% (18%) 22% 4% (47%) 37% Q3FY20 149 807 163 Q3FY19 122
Slide 6: Revenue Split – Q3FY20
6 Revenue Split – Q3FY20 Q3FY20 Q3FY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 15% 13% 12% 12% 72% 76% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 3% 2% 5% 3% 42% 52% 39% 43% 7% 4% Asia (ex- India)
Slide 7: Results Summary – 9MFY20
7 Results Summary – 9MFY20 Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 3,092 3,337 1,536 1,322 1,004 824 9MFY19 9MFY20 9MFY19 9MFY20 9MFY19 9MFY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Bio-Processing -24% -1% (18%) 0% 7% (47%) 18% 9MFY20 410 2,437 487 9MFY19 372 2,301 41
Slide 8: Revenue Split – 9MFY20
8 Revenue Split – 9MFY20 9MFY20 9MFY19 Segmental Revenue Split (%) Segmental Revenue Split (%) 15% 12% 13% 12% 73% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 5% 4% 44% 50% 39% 42% 7% 5% Asia (ex- India)
Slide 9: Profit & Loss (Consolidated) – Q3FY20 & 9MFY20
9 Profit & Loss (Consolidated) – Q3FY20 & 9MFY20 ₹ in Million except per share data Q3FY20 Q2FY20 Q3FY19 9MFY20 9MFY19 Particulars Y-o-Y (%) Y-o-Y (%) Unaudited Unaudited Unaudited Unaudited Unaudited Income from Operations 1,119 1,114 1,017 10% 3,337 3,092 8% Expenses 655 707 654 0% 1,992 1,928 3%
Slide 10: Balance Sheet (Consolidated) – 9MFY20
10 Balance Sheet (Consolidated) – 9MFY20 ₹ in Million 9MFY20 9MFY19 Particulars Unaudited Unaudited Assets Property, plant and equipment 2,021 1,626 Capital work-in-progress 176 112 Intangible assets 591 645 Goodwill 2,792 2,742 Other non-current assets 184 175 Current assets 3,484 2,663 Assets held
Slide 11: Results Summary – FY19
11 Results Summary – FY19 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,196 1,159 1,819 3,957 1,640 936 FY18 FY19 FY18 FY19 FY18 FY19 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% (1%) 10% (1%) 9% FY19 493 3,133 482 FY18 498 2,860 444 Note: 1.. On Consolidated B
Slide 12: Revenue Split – FY18 vs FY19
12 Revenue Split – FY18 vs FY19 FY19 FY18 Segmental Revenue Split (%) Segmental Revenue Split (%) 12% 12% 12% 13% 76% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 1% 4% 4% 47% 50% 41% 45% 3% 3% Asia (ex- Indi
Slide 13: Profit & Loss (Consolidated) – FY19
13 Profit & Loss (Consolidated) – FY19 ₹ in Million except per share data FY19 FY18 Particulars Y-o-Y (%) Audited Audited Income from Operations 4,196 3,957 6% Expenses 2,588 2,500 4% Profit from Operations before Other Income, Finance Costs and 1,608 1,457 10% Exceptional Item Other Income 50 14 26
Slide 14: Balance Sheet (Consolidated) – FY19
14 Balance Sheet (Consolidated) – FY19 ₹ in Million FY19 FY18 Particulars Audited Audited Assets Property, plant and equipment 1,618 1,667 Capital work-in-progress 105 105 Intangible assets 622 662 Goodwill 2,715 2,584 Other non-current assets 183 143 Current assets 2,821 2,107 Assets held for sale
Slide 15: Strong Financial Performance – FY19
15 Strong Financial Performance – FY19 ₹ in Million Revenue from Operations 2,500 EBIDTA & EBIDTA Margin (%) 50% 47% 45% 48% 4,196 3,957 2,000 45% 42% 46% 3,431 1,870 2,938 1,500 42% 1,654 44% 1,534 2,321 1,000 1,389 42% 931 40% 500 38% 0 36% FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY1
Slide 16: Strong Financial Performance – FY19
16 Strong Financial Performance – FY19 Net Working Capital (Days) Net Worth (₹ mn) 128 6,788 119 5,591 4,640 112 110 108 2,781 2,120 FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY 19 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.5 26% 27% 27% 26% 0.4 28% 24% 19% 18% 19% 0.1 0.01 0.02 FY
Slide 17: Shareholder Information
17 Shareholder Information Stock Data (As on 06th February 2020) Top 5 Institutional Holders (As on 24th January 2020) Institutions OS (%) Market Capitalization (₹) 19,504 mn ORBIMED ASIA III MAURITIUS 12.09 Shares Outstanding 111.64 mn HDFC SMALL CAP FUND 6.63 RELIANCE CAPITAL TRUSTEE CO. 1.70 Free
Slide 18: Thank You
Thank You Email: investor.realtions@advancedenzymes.com Advanced Enzyme Technologies Limited 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel.: +91-22-4170 3200 | Fax: + 91-22-25835159 | Web: www.advancedenzymes.com
Advanced Enzyme Technologies — Q3 FY2020 Earnings Presentation on 6ix